Hugh Jackman TRT: What Clinicians Should Tell Patients

Why Clinicians Are Hearing Hugh Jackman's Name in the Exam Room

Patients are arriving with screenshots. Hugh Jackman's physical transformation across nine Wolverine films between 2000 and 2017, and his continued lean physique into his mid-50s, has generated substantial media speculation about testosterone use. Clinicians need a structured response.

What Jackman Has and Has Not Said

Jackman told Oprah Winfrey in a 2013 interview that he had not used steroids for his X-Men preparation, attributing his physique to disciplined training and diet. He has not, at any point in a verifiable public record, confirmed testosterone replacement therapy. Media outlets citing "sources" or drawing inferences from his physique have not produced documented clinical confirmation.

Clinically, this matters. When a patient says "Hugh Jackman is on TRT, so why won't you prescribe it for me?" the accurate response is: there is no confirmed public record of that. The conversation should pivot quickly to the patient's own symptoms, labs, and clinical indications.

The Broader Pattern: Celebrity-Driven TRT Demand

Joe Rogan has spoken openly about his own TRT on his podcast, citing improved energy and body composition. Andrew Huberman, a Stanford neuroscientist, has discussed testosterone optimization publicly. These confirmed, self-reported cases are distinct from Jackman's situation, where no such confirmation exists. Clinicians can acknowledge the cultural conversation while redirecting to evidence.

A 2019 analysis published in JAMA Internal Medicine found that direct-to-consumer advertising and celebrity endorsements were associated with increased patient requests for testosterone prescriptions, often in men who did not meet diagnostic criteria (JAMA Intern Med, 2019). That pattern is relevant here.

What TRT Actually Is: A Clinical Primer for the Conversation

Testosterone replacement therapy is FDA-approved for the treatment of hypogonadism, defined as low serum testosterone combined with signs or symptoms attributable to deficiency. It is not approved for age-related testosterone decline alone, athletic performance, or body composition improvement in eugonadal men.

Diagnostic Criteria

The American Urological Association 2018 guidelines specify that diagnosis requires at least two morning fasting serum total testosterone measurements below 300 ng/dL, drawn between 7 a.m. And 11 a.m., on separate days, confirmed by a reliable assay (AUA, 2018). Symptoms must be present. Symptoms alone without biochemical confirmation do not justify initiation.

Free testosterone measurement adds value when sex hormone-binding globulin abnormalities are suspected, such as in obesity or hepatic disease. The Endocrine Society recommends free testosterone testing in those cases (J Clin Endocrinol Metab, 2018).

Approved Formulations and Doses

FDA-approved options include:

• Testosterone cypionate (intramuscular): 100 to 200 mg every 1 to 2 weeks, or 50 to 100 mg weekly to reduce peak-trough variability
• Testosterone enanthate (intramuscular): comparable dosing schedule to cypionate
• Testosterone gel 1% (AndroGel 1%): 50 to 100 mg applied daily to shoulders and upper arms
• Testosterone gel 1.62% (AndroGel 1.62%): 40.5 to 81 mg daily, titrated by serum levels at 14 and 28 days
• Testosterone nasal gel (Natesto): 11 mg three times daily; lower suppression of LH may partially preserve fertility
• Testosterone pellets (Testopel): 150 to 450 mg subcutaneously every 3 to 6 months

The FDA label for testosterone cypionate injection is available at accessdata.fda.gov.

The Cardiovascular Evidence Patients Will Ask About

TRAVERSE Trial Data

The TRAVERSE trial (N=5,246, mean age 63.3 years, mean baseline testosterone 227 ng/dL) was a randomized, double-blind, placebo-controlled trial examining whether testosterone gel 1.62% increased major adverse cardiovascular events (MACE) in hypogonadal men with or at high risk for cardiovascular disease. Published in the New England Journal of Medicine in 2023, it found no significant difference in MACE between testosterone and placebo over a median of 22 months (hazard ratio 0.96; 95% CI 0.78 to 1.17) (NEJM, 2023).

Atrial fibrillation was more frequent in the testosterone group (3.5% vs. 2.4%; P<0.001). Pulmonary embolism rates were also numerically higher. Clinicians should incorporate these specific signals into informed-consent discussions rather than citing TRAVERSE as an unconditional cardiovascular clearance.

Pre-TRAVERSE History

Before TRAVERSE, the 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial was halted early after a higher rate of cardiovascular events in the testosterone arm (NEJM, 2010). That trial enrolled frail older men, limiting generalizability, but the signal shaped a decade of prescribing caution. Patients who present TRAVERSE as proof TRT is "safe for the heart" should hear about TOM and the atrial fibrillation data in the same breath.

Polycythemia, Prostate, and Other Monitoring Requirements

Hematocrit Thresholds

Exogenous testosterone stimulates erythropoiesis. The AUA 2018 guideline recommends checking hematocrit at 3 to 6 months after initiation and then annually. Dose reduction or temporary discontinuation is indicated if hematocrit exceeds 54%, given increased thromboembolic risk. Patients who present at baseline with hematocrit above 50% require individualized risk assessment before starting therapy (AUA, 2018).

Prostate Safety

The Endocrine Society's 2018 clinical practice guideline states: "We recommend measuring PSA levels before starting testosterone therapy in men >40 years of age." Referral to urology is appropriate if PSA rises more than 1.4 ng/mL above baseline in any 12-month period on therapy, or if any single value exceeds 4.0 ng/mL (J Clin Endocrinol Metab, 2018).

The long-held concern that TRT promotes prostate cancer growth has not been confirmed in controlled trials for men with no prior history, but active or recent prostate cancer remains an absolute contraindication.

Sleep Apnea

Testosterone can worsen obstructive sleep apnea. Screen patients before initiation. If sleep apnea is untreated, address it first or proceed only after shared decision-making with documented discussion of the risk.

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. LH and FSH fall, intratesticular testosterone drops, and spermatogenesis is impaired. Azoospermia may develop within 3 to 4 months of starting TRT.

For patients who want to preserve fertility, alternatives include:

• Clomiphene citrate (off-label): 25 to 50 mg every other day to stimulate endogenous LH/FSH
• Human chorionic gonadotropin (hCG): 500 to 1,000 IU subcutaneously two to three times per week to maintain intratesticular testosterone and spermatogenesis
• Enclomiphene citrate (Natesto co-administration protocols): studied in combination regimens to maintain fertility while treating symptoms

A 2013 study in Fertility and Sterility found that concurrent hCG use maintained sperm production in 26 of 29 men on testosterone therapy (Fertil Steril, 2013). The American Society for Reproductive Medicine guidelines recommend discussing fertility preservation before any TRT initiation (ASRM, 2021).

What Patients Believe TRT Will Do vs. What Evidence Supports

Body Composition

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men 65 and older with a mean testosterone of 234 ng/dL, found that one year of testosterone gel increased lean mass by 3.0 kg and reduced fat mass by 1.6 kg compared to placebo (NEJM, 2016). Strength improvements were statistically significant but clinically modest in that population.

Body composition changes of the magnitude patients associate with celebrity physiques require years of structured resistance training, controlled nutrition, and genetic factors. TRT alone does not replicate an elite physique in a eugonadal man.

Sexual Function and Mood

The TTrials sexual function domain (N=470) found testosterone improved sexual activity and desire scores significantly versus placebo at 12 months (NEJM, 2016). The energy and vitality domain showed a statistically significant but modest effect. Cognitive function in that trial did not differ significantly between groups.

Bone Density

The TTrials bone domain (N=211) showed testosterone increased volumetric bone mineral density at the lumbar spine and femoral neck at 12 months. This is the domain with the most consistent evidence across age groups (NEJM, 2016).

A Clinical Framework for the "I Want What Hugh Jackman Has" Conversation

Patients who arrive citing a celebrity's physique as justification for TRT often conflate three separate questions: Is TRT indicated for me? Would TRT produce the physique I want? Is what that celebrity does confirmed and relevant to my situation?

Clinicians can use a structured three-part response:

Step 1: Establish the evidentiary baseline. Ask what the patient has read or heard. Distinguish between confirmed self-reports (Rogan, Huberman) and unconfirmed inference (Jackman). This is not dismissive; it is accurate. Patients generally respect a factual correction delivered without condescension.

Step 2: Anchor to the patient's own biology. Order morning serum total testosterone, LH, FSH, SHBG, CBC, PSA (if age 40 or older), and a metabolic panel. Symptoms plus biochemistry drive the clinical decision. The conversation cannot advance responsibly without this data.

Step 3: Calibrate expectations explicitly. If TRT is indicated, patients should hear three specific numbers before leaving: the 3.0 kg lean mass gain seen in TTrials at 12 months, the 54% hematocrit ceiling for dose adjustment, and the atrial fibrillation rate differential from TRAVERSE (3.5% vs. 2.4%). Concrete figures anchor expectations better than general statements.

The Endocrine Society guideline states directly: "We recommend against prescribing testosterone therapy to men with the sole aim of improving sexual function, energy, strength, or athletic performance when their testosterone levels are within the normal range." That sentence belongs in the conversation with eugonadal patients who present celebrity physiques as a clinical argument.

Monitoring Schedule After Initiation

A practical monitoring calendar derived from AUA and Endocrine Society recommendations:

• Baseline: Total testosterone (two morning draws), LH, FSH, SHBG, PSA (age >40), CBC, hepatic panel, lipids
• 3 to 6 months: Serum testosterone (target 400 to 700 ng/dL mid-cycle for injectables), hematocrit, symptom review
• 12 months: Full panel including PSA, lipids, bone density baseline if osteopenia risk exists
• Annually thereafter: Testosterone level, hematocrit, PSA, lipid panel, symptom reassessment

For injectable formulations, draw trough levels (immediately before the next injection) to avoid falsely elevated readings (Endocrine Society, 2018).

When to Refer

Refer to endocrinology or urology when:

• Testosterone remains below 300 ng/dL despite adequate replacement, suggesting secondary hypogonadism requiring pituitary evaluation
• PSA rise exceeds guideline thresholds
• Hematocrit exceeds 54% and does not respond to dose reduction or interval extension
• Patient desires fertility and standard clomiphene or hCG protocols have not restored sperm parameters within 6 months
• Klinefelter syndrome or another genetic etiology is suspected (karyotype, pituitary MRI)

Testosterone levels below 150 ng/dL on two separate morning draws warrant pituitary MRI to exclude a mass lesion before initiating replacement therapy (J Clin Endocrinol Metab, 2018).